Exicure Soars On Burixafor Data In Multiple Myeloma Trial

Exicure shares surged more than 65% to $8.69 after presenting positive topline phase 2 data for Burixafor at ASH: the CXCR4‑blocking small molecule, given with propranolol and G‑CSF, rapidly mobilized hematopoietic progenitor cells and enabled collection for autologous transplant. In the trial 17 of 19 patients (89.5%) collected ≥2 × 10^6 CD34+ cells/kg within two leukapheresis sessions (the other two required a third), with median neutrophil and platelet engraftment of 13 and 17.5 days respectively. Burixafor produced peak peripheral CD34+ levels within one hour—supporting same‑day administration and apheresis versus current FDA‑approved CXCR4 antagonists like plerixafor and motixafortide that need overnight pretreatment—indicating a potential operational and clinical advantage if confirmed in further studies.

Analysis

Exicure shares rallied more than 65% to $8.69 in overnight trading after the company presented positive topline phase 2 data for Burixafor at the ASH Annual Meeting, following a $5.33 close (up 3.50% on Monday). Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 on hematopoietic progenitor cells and was tested with propranolol and G-CSF to improve CD34+ stem cell mobilization for autologous hematopoietic cell transplantation in multiple myeloma.

In the 19-patient trial 17 of 19 participants (89.5%) met the primary endpoint of collecting at least 2 × 10^6 CD34+ cells/kg within two leukapheresis sessions and the remaining two required a third session; median neutrophil and platelet engraftment were 13 and 17.5 days respectively. Burixafor produced peak peripheral CD34+ levels within one hour, supporting same-day administration and apheresis versus current FDA-approved CXCR4 antagonists such as plerixafor and motixafortide that require overnight pretreatment.

The data signal a potential operational and clinical advantage that could displace incumbents if replicated in larger trials, but the result is based on a small (n=19) topline data set with no full safety or pivotal data disclosed. Key near-term risks are limited sample size, unreported detailed safety/adverse events, regulatory uncertainty, and typical biotech volatility; market moves should be viewed as event-driven pending confirmatory studies and filings.

Key Decisions for Investors

• Consider short-term event-driven exposure to XCUR to capture momentum around the ASH readout but size positions tightly and use stop-loss discipline given the small sample size and expected volatility
• Defer establishing a material long-term position until full dataset, detailed safety data and a sponsor plan for pivotal trials or regulatory interactions are disclosed
• Monitor catalysts closely: release of full data, safety/adverse-event details, initiation of pivotal studies, regulatory feedback, and any partnership or licensing announcements
• Manage downside by limiting allocation or using hedges given competitive incumbents (plerixafor, motixafortide) and remaining clinical and regulatory execution risk